Liu G, et al., J Altern Complement Integr Med 2021, 7: 179 DOI: 10.24966/ACIM-7562/100179
HSOA Journal of Alternative, Complementary & Integrative Medicine Research Article
The Effects of Ginsenoside Rg2 on Trastuzumab-Induced Cardiotoxicity Guang Liu1,2, Peipei Meng3, Yuetao Xie4 and Xiaoyong Qi2,4*
Cardiovascular department of the Fourth Hospital of Hebei Medical University,Shi Jiazhuang,Hebei Province,China
1
Graduate School,Hebei Medical University,Shi Jiazhuang,Hebei Province,China
2
The cadre ward,The 980th Hospital of the Joint Logistic Support Force of the People’s Liberation Army
3
Cardiovascular department of Hebei General Hospital,Shi Jiazhuang,Hebei Province,China
4
Abstract Objectives: Trastuzumab (TZM) shows significant effects in early-stage HER2-positive breast cancer, but it is also followed by severe cardiotoxicity. Ginsenoside Rg2 has been demonstrated usefully against myocardial injury and apoptosis. However, whether ginsenoside Rg2 can protect cardiomyocytes with TZM-induced toxicity is not clear. The study is to investigate its possible mechanism. Methods:30 wistar male rats were divided in 3 groups (control group, TZM group and TZM+Rg2 group), cardiac ultrasound was performed before and after the experiment; cardiomyocytes (H9C2) was divided in 3 groups (control group, TZM group and TZM+Rg2 group), Annexin V test and Western blot were performed in the experiment. Results: Ginsenoside Rg2 inhibited the deterioration of cardiac function in rats, ginsenoside Rg2 inhibited cardiomyocyte apoptosis, increased the expression of Caspase-3、Caspase-9 and BAX in cell experiment. Conclusions: Ginsenoside Rg2 could protect cardiomyocytes in TZM-induced toxicity and it might be via inhibiting cell apoptosis. Keywords: Breast cancer; Cardiotoxicity; Cell apoptosis; Ginsenoside Rg2; Trastuzumab
shows significant effects in early-stage breast cancer [1]. I the majority of patients with HER2-positive breast cancer, TZM has a significantly increasing in the overall survival [2].. However, TZM has a following cardiac side effects, including QTprolongation, bradycardia, hypertension, thromboembolic disease, congestive heart failure and ischemic heart disease, despite its beneficial effects [3,4]. Ginseng (Panax ginseng) is a traditional Chinese herbal medicine that has been widely used for thousands of years in East Asia, including China, Korea and Bhutan [5]. Ginsenoside is extracted from ginseng and plays the most important role among its components, including anti-inflammatory, antioxidant, anticancer, immunomodulatory and anti-stress effects [6-8]. Ginsenoside Rg2 is one compound of ginsenoside and has been proved multiple roles, including improving neurological performance, enhancing memory and exhibiting protective effects against hydrogen peroxide-induced injury and apoptosis in human cardiomyocytes [9-12]. This study aimed to investigate whether ginsenoside Rg2 could protect HCMs against TZM-induced toxicity in vitro and cardiac function in animal experiment.
Materials and Methods Animal experiments The experiment was approved by the Animal Care and Use Committee of Hebei Medical University; they were in compliancewiththeNationalInstitutesofHealthGuideforCareandUseofLaboratoryAnimals. 30 male wistar rats (160±10g) were randomly divided into 3 groups (n=10 per group):control group, TZM group and TZM+Rg2 group. TZM was given by intraperitoneal injection with a dose of 12mg/kg, then at a dose of 6mg/kg per day for 6 consecutive days, the ginsenoside Rg2 was given by intraperitoneal injection with a dose of 15mg/kg, the subsequent experiments were conducted after 24 hours, the control group was injected with the same dose of normal saline. Cardiac ultrasound was performed in the last day and Left Ventricular End-diastolic Diameter (LVEDD), Left Ventricular End-systolic Diameter (LVESD), Left Ventricular Ejection Fraction (LVEF) and Left Ventricular Fractional Shortening (LVFS) were recorded.
Introduction
Cell experiments
Trastuzumab (TZM) is a humanized monoclonal antibody that targets on Human Epidermal growth factor receptor 2 (HER2) and
Human primary HCMs (Applied Biological Materials, Inc.) were cultured in DMEM (Sigma‑Aldrich; Merck KGaA) containing 10% FBS (Thermo Fisher Scientific, Inc.), maintained at 37℃ and 5% CO2. They were divided in 3 groups as the same as the rats.TZM group was processed by TZM with a dose of 10μg/mL for 24h,TZM+Rg2 group was preprocessed by Rg2[purity>98% (by high-performance liquid chromatography analysis); MedChemExpress) with a dose of 0. 025mmol/ L for 24h, then the subsequent experiment was performed, the control was processed by the same dose of DMSO. Annex in V TEST and Western blotting were performed after TZM administration in 24h.
*Corresponding author: Xiaoyong Qi, Cardiovascular department of Hebei General Hospital,Shi Jiazhuang,Hebei Province,China, Tel: +86 031186095739; E-mail: 47126458@qq.com Citation: Liu G, Qi X (2021) The Effects of Ginsenoside Rg2 on Trastuzumab-Induced Cardiotoxicity. J Altern Complement Integr Med 7: 179. Received: June 04, 2021; Accepted: June 09, 2021; Published: June 16, 2021 Copyright: © 2021 Liu G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cell proliferation assay: HCMs (5x103 cells/well) were seeded in a 96-well plate in triplicate. The cells were subsequently treated with
Citation: Liu G, Qi X (2021) The Effects of Ginsenoside Rg2 on Trastuzumab-Induced Cardiotoxicity. J Altern Complement Integr Med 7: 179.
• Page 2 of 4 •
Rg2 and TZM, maintained for 24h at 37℃ and 5% CO2, MTT solution (5mg/ml) was added into every plate and then cultured in 3h at 37˚C. Remove the culture carefully and add DMSO in every plate. Using ELISA plate reader (Bio‑Rad Laboratories, Inc.) to check absorption of 490nm wave. Apoptosis assay: HCMs (2x105 cells/well) were seeded in a 6-well plate and then treated with Rg2 and TZM. Using Annexin V staining kit (BD Biosciences) to check the cell apoptosis. The cells were centrfugated for 5minutes by 500-1000r/min, abandoned the culture, washed by FBS once, centrfugated for 5minutes by 500-1000r/min again. Using 100ul marking solution to heavy-hanging cells, incubating without light for 10-15minutes. Add 5μl Annexin V and 10μl propidium Iodide, placed in a dark room for 15 minutes, using a FACSCanto II flow cytometer (BD Biosciences) to check the cell apoptosis. Western blotting: HCMs were rinsed and lysed using RIPAlysis buffer (EMD Millipore) containing a protease and phosphatase inhibitor. Subsequently, the cell lysates were vortexedon ice five times within 20 min and centrifuged for 10 minat 10,000 x g at 4℃. The protein concentration was determined using a bicinchoninic acid protein quantification kit (PromegaCorporation). Protein aliquots (30 µg) were subjected toSDS-PAGE on a 10% gel and subsequently transferred on to PVDF membranes (EMD Millipore). The membranes were blocked using 5% non‑fat milk for 1 h at room temperature. The membranes were then incubated with the following primary antibodies: Anti-phosphorylated (p)‑AKT (cat. no. ab38449),anti-pmTOR (cat. no. ab84400), anti-autophagy protein 5(ATG5, cat. no. ab109490), anti-beclin 1 (cat. no. ab210498),anti-microtubule associated protein 1 light chain 3α (LC3,cat. no. ab62721) overnight at 4˚C. All primary antibodies wereused at a 1:200 dilution and were purchased from Abcam. Following washing with PBS, the membranes were incubated with horseradish peroxidase‑conjugated secondary antibodies (Abcam) for 1 h at room temperature. An ECL reagent kit (SantaCruz Biotechnology, Inc.) was used to visualize the immu-noreactive bands according to the manufacturer’s protocol. Protein band intensities were quantified using Image J software (v1.8.0.112; National Institutes of Health). β‑actin (1:200 dilution; cat. no. ab8227; Abcam) acted as the internal control.
Control group
TZM group
LVEDD(mm)
6.32±0.54
6.34±0.40
TZM+Rg2 group 6.25±0.43
LVESD(mm)
3.36±0.62
3.31±0.81
3.26±0.59
LVEF (%)
78.05±5.81
80.72±8.10
81.77±6.46
LVFS (%)
49.25±7.39
51.60±9.19
52.7±8.17
Table 1: Echocardiographic index of left ventricle in three groups of rats.
Figure 1: Changes of cardiac LVEDD in three groups of rats after medication administration. *Compared with control group (P<0.05), # Compared with control group (P>0.05)
Statistical analyses All data are presented as mean ± standard deviation. One-way analysis of variance was used to assess statistical differences; pair wise analysis was performed by posthoc Tukey tests. All statistical analyses were performed using SPSS Statistics, version 19.0 (IBM, Armonk, NY, USA). Differences with P < 0.05 were considered statistically significant.
Results The protective effect of ginsenoside Rg2 on cardiac function in rats Before administration there was no difference among 3 groups in LVEDD, LVESD, LVEF and LVFS (table 1); there was an obvious increasing of LVEDD and LVESD and an obvious decreasing of LVEF and LVFS in TZM group, it was statistically significant compared with control group (P<0.05); in TZM+Rg2 group, the changes were not obvious and there was no statistical difference between it and control group (P>0.05 Figures 1-4). J Altern Complement Integr Med ISSN: 2470-7562, Open Access Journal DOI: 10.24966/ACIM-7562/100179
Figure 2: Changes of cardiac LVESD in three groups of rats after medication administration. *Compared with control group (P<0.05), # Compared with control group (P>0.05)
There was no statistical difference compared with control group, P>0.05.
The protective effects of ginsenoside Rg2 in TZM-induced cardiotoxicity of HCMs In the colone test, we checked the cell proliferation, investigated that TZM could inhibit the proliferation and pretreatment with ginsenoside Rg2 improved the proliferation (Figure 5). In Annex in V test, we checked the cell apoptosis, TZM obviously promoted the apoptosis, pretreatment with ginsenoside Rg2 prevented the process (Figure 6).In western blot test, we checked the expressions of Caspase-3, Caspase-9 and BAX in the cells, there was a significant up-regulation in TZM group compared with control group, pretreatment with ginsenoside Rg2 could inhibit the up-regulation (Figure 7). Volume 7 • Issue 3 • 100179
Citation: Liu G, Qi X (2021) The Effects of Ginsenoside Rg2 on Trastuzumab-Induced Cardiotoxicity. J Altern Complement Integr Med 7: 179.
• Page 3 of 4 •
Figure 3: Changes of cardiac LVEF in three groups of rats after medication administration. *Compared with control group (P<0.05), # Compared with control group (P>0.05)
Figure 6: Effects of ginsenoside Rg2 on cell apoptosis. *Compared with control group (P<0.05), # Compared with control group (P>0.05)
Figure 4: Changes of cardiac LVFS in three groups of rats after medication administration. *Compared with control group (P<0.05), # Compared with control group (P>0.05) Figure 7: Effects of ginsenoside Rg2 on apoptosis-related proteins.
Discussion In this study, we found that TZM induced toxicity via animal experiment and in vitro model of HCMs. The affection of HCMs included decreasing cell proliferation, increasing cell apoptosis and up-regulating the expressions of Caspase-3, Caspase-9 and BAX. However, the TZM-induced cardiotoxicity and Caspase-3, Caspase-9 and BAX up-regulation were reversed by ginsenoside Rg2. In animal experiment, TZM induced obvious cardiac disfunction showen as heart dilatation and LVEF decreasing, but pretreatment with ginsenoside Rg2 prevent the proceeding.
Figure 5: Effects of ginsenoside Rg2 on cell proliferation. *Compared with control group (P<0.05), # Compared with control group (P>0.05) J Altern Complement Integr Med ISSN: 2470-7562, Open Access Journal DOI: 10.24966/ACIM-7562/100179
Ginseng has an important medical value and various compound prepatations have been used to treat cardiac disease. Ginsenoside Rg2 is a constituent of panaxatriol, previous studies have showen that ginsenoside Rg2 can resistant hypoxia injuries, reduce cell apoptosis and protect myocardial cells [13,14]. Recently, the other effects of ginsenoside Rg2 were reported more and more. Ginsenoside Rg2 can repair the UV-induced DNA damage, possibly via the pathway of regulating the P53 protein [15,16]. A reported study showed that ginsenoside Rg2 exerted protective effects against hydrogen peroxide‑induced injury and apoptosis in HCMs [17]. Furthermore, ginsenoside Volume 7 • Issue 3 • 100179
Citation: Liu G, Qi X (2021) The Effects of Ginsenoside Rg2 on Trastuzumab-Induced Cardiotoxicity. J Altern Complement Integr Med 7: 179.
• Page 4 of 4 •
Rg2 could increase autophagy and activated the p53/AMPK signaling pathway in MCF-7 breast cancer cells and decrease lipopolysac charide-induced Bax, caspase-3 and -9 expressions and exerted an antiapoptotic effect in neurons [18,19]. Furthermore, Wang et al., [20] investigated that ginsenoside Rg2 could inhibit the proliferation of breast cancer cells in vitro. Collectively, in the study, we found that TZM could cause cell apoptosis, heart enlargement and cardiac disfunction, up-regulate the expressions of Caspase-3, Caspase-9 and BAX. It revealed that TZM induced cardiomyocyte injuries might be by cell apoptosis. Pretreatment with ginsenoside Rg2 inhibited the deterioration of cardiac function, down-regulate the expressions of Caspase-3, Caspase-9 and BAX, prompted that ginsenoside Rg2 could protect cardiomyocyte possibly via inhibiting cell apoptosis. Ginsenoside Rg2 may serve as a potential clinical agent to prevent TZM‑related cardiotoxicity and may provide significant beneficial effects for patients with breast cancer. However, the data presented in this study requires further in vivo validation prior to the clinical application of ginsenoside Rg2.
Declaration of Conflicting Interest The authors declare that there is no conflict of interest.
Funding No funding was received.
References 1. Gershon N, Berchenko Y, Hall PS, Goldstein DA (2019) Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage. Cost Eff Resour Alloc 17: 5. 2. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, et al. (2011) Adjuvant trastuzumab in HER2‑positive breast cancer. N Engl J Med 365: 1273‑1283. 3. Mazzotta M, Krasniqi E, Barchiesi G, Pizzuti L, Tomao F, et al. (2019) Long‑term safety and real‑world effectiveness of trastuzumab in breast cancer. J Clin Med 8: 254. 4. Sato A, Yoshihisa A, Miyata‑Tatsumi M, Oikawa M, Kobayashi A, et al. (2019) Valvular heart disease as a possible predictor of trastuzumab‑induced cardiotoxicity in patients with breast cancer. Mol Clin Oncol 10: 37‑42. 5. Xu QM, Jia D, Gao HW, Zhang MM, He WJ, et al. (2013) In vitro and in vivo protective effects of gingenosides on acute renal injury induced by cantharidin.J Functional Foods 5: 2012‑2018.
7. Fu W, Sui D, Yu X, Gou D, Zhou Y, et al. (2015) Protective effects of ginsenoside Rg2 against H2O2-induced injury and apoptosis in H9c2 cells. Int J Clin Exp Med 8: 19938-19947. 8. Gou D, Pei X, Wang J, Wang Y, Hu C, et al. (2020) Antiarrhythmic effects of ginsenoside Rg2 on calcium chloride-induced arrhythmic without oral toxicity. Journal of Ginseng Research 44: 717-724. 9. Zhang G, Liu A, Zhou Y, San X, Jin T, et al. (2008) Panax ginseng ginsenoside‑Rg2 protects memory impairment via anti‑apoptosis in a rat model with vascular dementia. J Ethnopharmacol 115: 441‑448. 10. Fan Y, Wang N, Rocchi A, Zhang W, Vassar R, et al. (2017) Identification of natural products with neuronal and metabolic benefits through autophagy induction. Autophagy 13: 41‑56. 11. Chung Y, Jeong S, Choi HS, Ro S, Lee JS, et al. (2018) Upregulation of autophagy by Ginsenoside Rg2 in MCF‑7 cells. Anim Cells Syst (Seoul) 22: 382‑389. 12. Fu W, Sui D, Yu X, Gou D, Zhou Y, et al. (2015) Protective effects of ginsenoside Rg2 against H2O2‑induced injury and apoptosis in H9c2 cells. Int J Clin Exp Med 8: 19938-19947. 13. Sun Y, Liu Y, Chen K (2016) Roles and mechanisms of ginsenoside in cardiovacular diseases: Progress and Perspectives. Science China (Life Sciences) 59: 292-298. 14. Cui J, Wang J, Zheng M, Gou D, Liu C, et al. (2017) Ginsenoside Rg2 Protects PC12 cells against β-amyloid25-35 -induced apoptosis via the phosphoinositide 3-kinase/Akt pathway. Chemico-Biological Interactions 9: 152-161. 15. Chung Y, Jeong S, Choi HS, Ro S, Lee JS, et al. (2018) UPregulation of AutoPhagy by Ginsenoside Rg2 in MCF-7 Cells. Animal cells and systems 22: 382-389. 16. Chung YH, Jeong SA, Choi HS, Ro S, Lee JS, et al. (2018) Protective effects of ginsenoside Rg2 and astaxanthin mixture against UVB-induced DNA damage. Animal cells and systems 22: 400-406. 17. Fu W, Sui D, Yu X, Gou D, Zhou Y, et al. (2015) Protective effects of ginsenoside Rg2 against H2O2‑induced injury and apoptosis in H9c2 cells. Int J Clin Exp Med 8: 19938‑19947. 18. Chung Y, Jeong S, Choi HS, Ro S, Lee JS, et al. (2018) Upregulation of autophagy by Ginsenoside Rg2 in MCF‑7 cells.Anim Cells Syst (Seoul) 22: 382‑389. 19. Chung YH, Jeong SA, Choi HS, Ro S, Lee JS, et al. (2018) Protective effects of ginsenoside Rg2 and astaxanthin mixtureagainst UVB‑induced DNA damage. Anim Cells Syst (Seoul) 22: 400‑406. 20. Wang CZ, Aung HH, Zhang B, Sun S, Li XL, et al. (2008) Chemopreventive effects of heat-processed Panax quinquefolius root on human breast cancer cells. Anticancer Res 28: 2545‑2551.
6. Christensen LP (2009) Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. J Adv Food Nutr Res 55: 1-99.
J Altern Complement Integr Med ISSN: 2470-7562, Open Access Journal DOI: 10.24966/ACIM-7562/100179
Volume 7 • Issue 3 • 100179
Advances In Industrial Biotechnology | ISSN: 2639-5665
Journal Of Genetics & Genomic Sciences | ISSN: 2574-2485
Advances In Microbiology Research | ISSN: 2689-694X
Journal Of Gerontology & Geriatric Medicine | ISSN: 2381-8662
Archives Of Surgery And Surgical Education | ISSN: 2689-3126
Journal Of Hematology Blood Transfusion & Disorders | ISSN: 2572-2999
Archives Of Urology
Journal Of Hospice & Palliative Medical Care
Archives Of Zoological Studies | ISSN: 2640-7779
Journal Of Human Endocrinology | ISSN: 2572-9640
Current Trends Medical And Biological Engineering
Journal Of Infectious & Non Infectious Diseases | ISSN: 2381-8654
International Journal Of Case Reports And Therapeutic Studies | ISSN: 2689-310X
Journal Of Internal Medicine & Primary Healthcare | ISSN: 2574-2493
Journal Of Addiction & Addictive Disorders | ISSN: 2578-7276
Journal Of Light & Laser Current Trends
Journal Of Agronomy & Agricultural Science | ISSN: 2689-8292
Journal Of Medicine Study & Research | ISSN: 2639-5657
Journal Of AIDS Clinical Research & STDs | ISSN: 2572-7370
Journal Of Modern Chemical Sciences
Journal Of Alcoholism Drug Abuse & Substance Dependence | ISSN: 2572-9594 Journal Of Allergy Disorders & Therapy | ISSN: 2470-749X Journal Of Alternative Complementary & Integrative Medicine | ISSN: 2470-7562 Journal Of Alzheimers & Neurodegenerative Diseases | ISSN: 2572-9608 Journal Of Anesthesia & Clinical Care | ISSN: 2378-8879 Journal Of Angiology & Vascular Surgery | ISSN: 2572-7397 Journal Of Animal Research & Veterinary Science | ISSN: 2639-3751 Journal Of Aquaculture & Fisheries | ISSN: 2576-5523 Journal Of Atmospheric & Earth Sciences | ISSN: 2689-8780 Journal Of Biotech Research & Biochemistry Journal Of Brain & Neuroscience Research Journal Of Cancer Biology & Treatment | ISSN: 2470-7546 Journal Of Cardiology Study & Research | ISSN: 2640-768X Journal Of Cell Biology & Cell Metabolism | ISSN: 2381-1943 Journal Of Clinical Dermatology & Therapy | ISSN: 2378-8771 Journal Of Clinical Immunology & Immunotherapy | ISSN: 2378-8844 Journal Of Clinical Studies & Medical Case Reports | ISSN: 2378-8801 Journal Of Community Medicine & Public Health Care | ISSN: 2381-1978 Journal Of Cytology & Tissue Biology | ISSN: 2378-9107 Journal Of Dairy Research & Technology | ISSN: 2688-9315 Journal Of Dentistry Oral Health & Cosmesis | ISSN: 2473-6783 Journal Of Diabetes & Metabolic Disorders | ISSN: 2381-201X Journal Of Emergency Medicine Trauma & Surgical Care | ISSN: 2378-8798
Journal Of Nanotechnology Nanomedicine & Nanobiotechnology | ISSN: 2381-2044 Journal Of Neonatology & Clinical Pediatrics | ISSN: 2378-878X Journal Of Nephrology & Renal Therapy | ISSN: 2473-7313 Journal Of Non Invasive Vascular Investigation | ISSN: 2572-7400 Journal Of Nuclear Medicine Radiology & Radiation Therapy | ISSN: 2572-7419 Journal Of Obesity & Weight Loss | ISSN: 2473-7372 Journal Of Ophthalmology & Clinical Research | ISSN: 2378-8887 Journal Of Orthopedic Research & Physiotherapy | ISSN: 2381-2052 Journal Of Otolaryngology Head & Neck Surgery | ISSN: 2573-010X Journal Of Pathology Clinical & Medical Research Journal Of Pharmacology Pharmaceutics & Pharmacovigilance | ISSN: 2639-5649 Journal Of Physical Medicine Rehabilitation & Disabilities | ISSN: 2381-8670 Journal Of Plant Science Current Research | ISSN: 2639-3743 Journal Of Practical & Professional Nursing | ISSN: 2639-5681 Journal Of Protein Research & Bioinformatics Journal Of Psychiatry Depression & Anxiety | ISSN: 2573-0150 Journal Of Pulmonary Medicine & Respiratory Research | ISSN: 2573-0177 Journal Of Reproductive Medicine Gynaecology & Obstetrics | ISSN: 2574-2574 Journal Of Stem Cells Research Development & Therapy | ISSN: 2381-2060 Journal Of Surgery Current Trends & Innovations | ISSN: 2578-7284 Journal Of Toxicology Current Research | ISSN: 2639-3735 Journal Of Translational Science And Research
Journal Of Environmental Science Current Research | ISSN: 2643-5020
Journal Of Vaccines Research & Vaccination | ISSN: 2573-0193
Journal Of Food Science & Nutrition | ISSN: 2470-1076
Journal Of Virology & Antivirals
Journal Of Forensic Legal & Investigative Sciences | ISSN: 2473-733X
Sports Medicine And Injury Care Journal | ISSN: 2689-8829
Journal Of Gastroenterology & Hepatology Research | ISSN: 2574-2566
Trends In Anatomy & Physiology | ISSN: 2640-7752
Submit Your Manuscript: https://www.heraldopenaccess.us/submit-manuscript Herald Scholarly Open Access, 2561 Cornelia Rd, #205, Herndon, VA 20171, USA. Tel: +1 202-499-9679; E-mail: info@heraldsopenaccess.us http://www.heraldopenaccess.us/